Skip to main content

Table 2 Variants associated with PFS in multivariate Cox proportional hazards regression model

From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Variables B SE Wald P HR 95.0 % CI for HR
Pathology
 Non-adenocarcinoma      1.00  
 Adenocarcinoma −1.26 0.54 5.36 0.021 0.285 0.10~0.83
ECOG PS
 ≥2      1.00  
 0–1 −1.01 0.53 3.71 0.054 0.363 0.13~1.02
Groups
 Stable group      1.00  
 Ascend group −0.70 0.28 6.43 0.011 0.498 0.30~0.85
  1. PFS progression-free survival, ECOG Eastern Cooperative Oncology Group, PS performance status